• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OGI

    Organigram Global Inc.

    Subscribe to $OGI
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.

    IPO Year:

    Exchange: NASDAQ

    Website: organigram.ca

    Peers

    $HEXO

    Recent Analyst Ratings for Organigram Global Inc.

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    4/15/2024Neutral → Buy
    Alliance Global Partners
    1/13/2023Hold → Buy
    Stifel
    1/12/2022Hold → Speculative Buy
    Canaccord Genuity
    1/12/2022$5.70 → $5.30Overweight
    Cantor Fitzgerald
    12/8/2021$5.50 → $5.70Overweight
    Cantor Fitzgerald
    See more ratings

    Organigram Global Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Organigram Reports Record Second Quarter Fiscal 2025 Results

      Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

      5/12/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global's Collective Project Wins Big at the 2025 High Spirits Awards in California

      Wins gold medal for Blood Orange, Yuzu & Vanilla and platinum medal for Mango, Pineapple & Coconut Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce that its recently acquired business, Collective Project, has won recognition at the 2025 High Spirits Awards only a few short months following the launch of the brand in the U.S. The brand received a gold award for Blood Orange, Yuzu & Vanilla and a platinum award for Mango, Pineapple & Coconut hemp-derived THC beverages. High Spirits Awards is a competition launched by L.A. Spirits Awards in 2023 to identify and reward excellence among the growi

      5/7/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export Awards

      Award recognizes exceptional export growth, product innovation, and global market leadership Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), ("the Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce it has been named Exporter of the Year by Opportunities New Brunswick ("ONB") as part of the 2025 New Brunswick Export Awards, ONB's flagship annual event recognizing the successes and innovative approaches of New Brunswick's many exporting companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505021217/en/ This honour recognizes Organigram's significant growth in international cannab

      5/5/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025

        Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2025 ended March 31, 2025, on Monday, May 12, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Monday, May 12, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766371 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a co

      5/2/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global Congratulates Mark Carney on Election Win

      Urges new government to work with industry to help legal cannabis industry fuel Canada's economic growth Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, congratulates Prime Minister Mark Carney on the results of the 2025 federal election and urges policymakers to act swiftly in recognizing and elevating the cannabis sector as a critical pillar in Canada's economic growth strategy. "Congratulations to Prime Minister Carney on his party's victory and to Opposition Leader Pierre Poilievre for his party's strong showing, as well as all who put themselves forward as candidates," said Beena Goldenberg, CEO of Organigr

      4/29/25 7:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global's Products Recognized at the CNB Awards

      SHRED, Edison, and Trailblazer Recognized for Excellence in Branding and Product Innovation Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce that three of its consumer brands — SHRED, Edison, and Trailblazer — earned honours at the recent CNB Leadership Conference and the Cannabis NB Cup. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424458385/en/ Inspired by the legacy events that have shaped cannabis culture over the years, the Cannabis NB Cup celebrates the best in grow — with winners chosen by those who matter most, our co

      4/24/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global Shares Recording of its OG Investor Session

      OG Investor Session includes presentations from Organigram Global's senior leadership team, tours of its five state-of-the-art facilities, and a live investor Q&A session Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram Global"), Canada's #1 cannabis company by market share, is pleased to share the full recording of its recently held OG Investor Session, now available online for shareholders, analysts, and industry stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422567368/en/ To access a recording of the event please click here or visit www.organigram.ca/investors. "This session was a

      4/22/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Abacus Data Poll Reveals that Most Canadians See Cannabis as a Key Pillar of Canada's Economic Future

      Clear majority believes Canada's $7.4 billion legal cannabis industry should be empowered to grow amid rising global trade tensions Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, today released new public opinion data showing strong national support for growing Canada's economy through homegrown industries, including the legal cannabis sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250416457263/en/ The national survey, commissioned by Organigram Global and conducted by Abacus Data between April 3–8, 20251, arrives at a pivotal moment for Canad

      4/16/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global to Host the OG Investor Session, its Inaugural Virtual Event for Investors, and Announcement of Name Change on TSX and NASDAQ

      Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram Global"), the cannabis leader in Canada by market share, is pleased to announce its inaugural virtual investor event, the OG Investor Session, taking place on April 10, 2025, at 4pm EST. This online event offers investors a front-row seat to Organigram Global's next chapter. Attendees will gain valuable insights into the Company's growth trajectory, engage directly with leadership on key industry trends, and get a behind-the-scenes look at the innovation and strategy driving Organigram Global forward. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250402

      4/2/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Enters U.S. Through Acquisition of Collective Project Beverages

      Acquisition Marks Commercial Market Entry in the Fast-Growing Hemp-Derived THC Beverage Category in the U.S. and the Emerging Canadian Cannabis Beverage Category Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Collective Project Limited ("CPL") for upfront consideration of approximately C$6.2 million, potential milestone payments and potential earnout payments totaling in the aggregate up to C$24M for the twelve-month periods ending September 30, 2025 and September 30, 2026. This press release features multimedia. View the full

      4/1/25 7:47:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Organigram Global Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on OrganiGram

      Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

      7/17/24 12:18:49 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Alliance Global Partners

      Alliance Global Partners upgraded OrganiGram from Neutral to Buy

      4/15/24 8:40:01 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Stifel

      Stifel upgraded OrganiGram from Hold to Buy

      1/13/23 7:36:46 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Canaccord Genuity

      Canaccord Genuity upgraded OrganiGram from Hold to Speculative Buy

      1/12/22 7:59:18 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on OrganiGram Holdings with a new price target

      Cantor Fitzgerald reiterated coverage of OrganiGram Holdings with a rating of Overweight and set a new price target of $5.30 from $5.70 previously

      1/12/22 4:57:31 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on OrganiGram Holdings with a new price target

      Cantor Fitzgerald reiterated coverage of OrganiGram Holdings with a rating of Overweight and set a new price target of $5.70 from $5.50 previously

      12/8/21 5:14:59 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by CIBC

      CIBC upgraded OrganiGram from Sector Underperform to Neutral

      5/11/21 8:02:24 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram downgraded by CIBC

      CIBC downgraded OrganiGram from Neutral to Sector Underperform

      4/14/21 7:18:16 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram Holdings downgraded by CIBC with a new price target

      CIBC downgraded OrganiGram Holdings from Neutral to Underperformer and set a new price target of $3.25 from $5.00 previously

      4/14/21 7:04:11 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram Holdings downgraded by CIBC with a new price target

      CIBC downgraded OrganiGram Holdings from Neutral to Underperform and set a new price target of $3.25 from $5.00 previously

      4/14/21 7:04:11 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Organigram Global Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of Name Change to Organigram Global Inc.

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on March 24, 2025 (the "Meeting"). Shareholder Approval of the Name Change and Articles of Amendment At the Meeting, a special resolution approving an amendment to the articles of the Company to change the name of the Company to "Organigram Global Inc." (the "Name Change"), was approved by the affirmative vote of 95.778% of the votes represented at the Meeting. The Name Change remains subject to regulatory approvals, including the approval of the TSX. The TSX has conditionally ap

      3/24/25 8:30:00 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Craig Harris to Board of Directors

      Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

      7/29/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Karina Gehring to Board of Directors

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), announced the appointment of Karina Gehring to the Organigram Board of Directors at the Company's annual general and special meeting held on January 18, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240119151071/en/Karina Gehring (Photo: Business Wire) "We are thrilled to welcome Karina to our Board of Directors. Her extensive expertise in marketing and brand management combined with her ongoing experience with BAT will be a tremendous asset to our Board," said Peter Amirault, Board Chair, Organigram. Karina is one of two directors (includi

      1/19/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of C$124.6 Million Investment from BAT

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on January 18, 2024 (the "Meeting"). Election of Directors Each of the nine nominees listed in the Company's management information circular dated December 20, 2023 (the "Circular") provided in connection with the Meeting were elected as directors of the Company. The Company received proxies and virtual votes at the Meeting as set out below: Nominee # Votes For % of Votes For # Votes Against % of Votes Against Peter Amirault 21,048,219

      1/18/24 8:00:00 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

      Special Meeting to Approve $124.6 Million Investment from BAT at $3.2203/share and Creation of "Jupiter" Strategic Investment Pool Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the "Circular") and related materials (the "Meeting Materials") for its annual and special meeting (the "Meeting") of the holders of its common shares (the "Shareholders") to be held on January 18, 2024. In addition to routine annual business to be conducted (including the election of directors and the appointment of an auditor), Shareholders at the Meeting wil

      12/29/23 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Greg Guyatt as Chief Financial Officer

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) is pleased to announce that Greg Guyatt CPA, CA, formerly of Phoena Holdings Inc. ("Phoena"), has been appointed to the role of Chief Financial Officer effective January 8, 2024. Mr. Guyatt will lead Organigram's Finance and IT divisions and will report directly to Beena Goldenberg, Organigram's Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218771633/en/Greg Guyatt (Photo: Business Wire) Mr. Guyatt is a seasoned financial executive with over 25 years of international public company and private equity backed company experi

      12/18/23 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Resignation of Board Member

      Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announces today that Ms. Caroline Ferland has resigned from the Board of Directors ("the Board") effective immediately. Ms. Ferland was a board member nominee appointed by BAT. "In her short time on the Board, Ms. Ferland made considerable contributions to Organigram," said Peter Amirault, Chair of Organigram's Board of Directors. "In addition to providing meaningful involvement on the strategic planning and corporate governance fronts, Ms. Ferland used her extensive international experience in legal and regulatory matters to support the Company, providing solid strat

      9/1/23 6:00:00 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBD Oil Market to Hit Nearly US$137 Billion by 2029

      FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The CBD oil market is expected to witness an astounding CAGR of 38.90% from 2021 until 2029, climbing from $9.86 billion to $136.64 billion. There are several reasons behind the projected growth such a growing number of CBD-infused skincare products, increased use of THC and CBD in pain management and treatment, rising sales in both retail stores and online, expanding research, and increasing demand for ingestible products. Governments around the world have also begun opening up more doors for CBD, with a recent Health Canada report suggesting legal framework to broaden retail CBD sales across

      8/23/22 8:50:00 AM ET
      $CGC
      $CRON
      $FLGC
      $OGI
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Organigram Appoints Beena Goldenberg as Chief Executive Officer

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce Beena Goldenberg, formerly Chief Executive Officer of The Supreme Cannabis Company Inc. and previously Chief Executive Officer at Hain-Celestial Canada, ULC, has been appointed the Company's new Chief Executive Officer (CEO). Ms. Goldenberg will assume the role effective September 9, 2021. An accomplished business leader, Ms. Goldenberg has more than 30 years of experience in consumer-packaged goods, manufacturing and marketing. As President and CEO of The Supreme Cannabis Company Inc., she successfully achie

      8/4/21 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Appoints Senior Vice President of Marketing

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading producer of cannabis, is pleased to announce the appointment of Megan McCrae as the Company's Senior Vice President of Marketing and Communications. Ms. McCrae will assume her new role effective today. A seasoned marketing expert, Ms. McCrae has 17 years experience in consumer packaged goods marketing and sales management, brand building and consumer insights. Ms. McCrae is a cannabis industry veteran, having most recently served as Chief Marketing Officer of Aphria Inc. where she led the company's brand and product strategy including brand and portfolio manage

      5/31/21 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Organigram Global Inc. Financials

    Live finance-specific insights

    See more
    • Organigram Reports Record Second Quarter Fiscal 2025 Results

      Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

      5/12/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025

        Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2025 ended March 31, 2025, on Monday, May 12, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Monday, May 12, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766371 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a co

      5/2/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Enters U.S. Through Acquisition of Collective Project Beverages

      Acquisition Marks Commercial Market Entry in the Fast-Growing Hemp-Derived THC Beverage Category in the U.S. and the Emerging Canadian Cannabis Beverage Category Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Collective Project Limited ("CPL") for upfront consideration of approximately C$6.2 million, potential milestone payments and potential earnout payments totaling in the aggregate up to C$24M for the twelve-month periods ending September 30, 2025 and September 30, 2026. This press release features multimedia. View the full

      4/1/25 7:47:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Reports First Quarter Fiscal 2025 Results

      17% growth in net revenue to $42.7 million year-over-year $2.3 million growth in international sales year-over-year Adjusted EBITDA1 of $1.4 million versus $0.1 million in the prior year period Completed acquisition of Motif to become recreational cannabis market leader in Canada Launched Edison Sonics with proprietary FAST™ nanoemulsion technology, clinically validated to have up to 50% faster onset and nearly 2x impact of cannabinoids at peak Strong balance sheet with negligible debt, and a pro-forma cash position of $113 million2 Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its resu

      2/11/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram to Report First Quarter Fiscal 2025 Results on February 11, 2025

      Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 11, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I967665 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 min

      2/4/25 6:00:00 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Reports Fourth Quarter and Fiscal 2024 Results

      Fiscal 2024 net revenue of $159.8 million 17.6% year-over-year growth in Organigram's recreational shipped sales in Fiscal 2024 Q4 Fiscal 2024 adjusted gross margin1 of 37% Q4 Fiscal 2024 adjusted EBITDA2 of $5.9 million or 13% of net revenue Q4 Fiscal 2024 cash flow from operations of $8.9 million Became Canada's largest cannabis company by market share following the acquisition of Motif Labs subsequent to year end Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer ("LP") of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 ("Q4 Fiscal 2024" or "Fiscal 2024"). All f

      12/18/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram to Report Fourth Quarter and Fiscal 2024 Results on December 18, 2024

      Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, December 18, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766465 To ensure you are connected for the full call, we suggest registering a day in advance or at mi

      12/11/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Acquires Motif, Becoming Canada's Largest Cannabis Company by Market Share

      Transformational Acquisition Results in Cannabis Pure Play Leader, Coast-to-Coast Geographic Strength and Proven Excellence in Consumer-Focused Innovation, Cultivation, Product Development, Extraction and Manufacturing Combination results in #1 market share position in the Canadian recreational cannabis market1 Catapults Organigram into the #1 position in the vape category and accelerates the Company's market share in the fast-growing infused pre-roll segment1 Strong brand portfolio now anchored by Organigram's "SHRED" and Motif's "BOXHOT" - two of Canada's beloved cannabis brands Highly complementary product portfolios with expanded geographic reach Organigram gains strategi

      12/6/24 9:17:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Reports Third Quarter Fiscal 2024 Results

      Net revenue of $41.1 million increased 25% over the prior year period Adjusted EBITDA1 of $3.5 million versus $(2.9) million over the prior year period Established European foothold with a strategic investment in Sanity Group, a leading German cannabis company Completed landmark clinical study on FAST™ nanoemulsion technology showing faster onset, improved bioavailability of ingestible products Pro-forma cash position of $173 million2 Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 ("Q3 Fiscal 2024"). THIRD QUARTER HIGHLIGHTS Third q

      8/13/24 6:30:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024

      Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, August 13, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676663358 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes

      8/6/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Organigram Global Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      12/10/24 7:10:15 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      9/3/24 9:30:26 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      1/25/24 5:23:26 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      11/8/23 5:07:55 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      2/1/22 9:53:02 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Organigram Holdings Inc. (Amendment)

      SC 13G/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      11/16/21 8:32:50 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Organigram Holdings Inc. (Amendment)

      SC 13G/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      8/16/21 3:40:39 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Organigram Holdings Inc.

      SC 13D - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      3/19/21 4:10:58 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      2/16/21 11:16:05 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Organigram Global Inc. SEC Filings

    See more
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/12/25 7:39:04 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/7/25 9:38:26 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/5/25 11:48:28 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/2/25 8:28:53 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      4/29/25 3:31:29 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      4/24/25 5:32:16 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      4/22/25 11:13:24 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      4/16/25 4:48:52 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Holdings Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      4/2/25 1:47:04 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Holdings Inc.

      6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

      4/1/25 9:40:42 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care